Last updated: July 29, 2025
Introduction
Brazilian patent BR112017014994, titled "Pharmaceutical Composition Containing Melatonin and Method of Use," was granted in 2017, representing an important step in intellectual property protection within Brazil’s pharmaceutical sector. This patent provides exclusive rights to the inventor over specific formulations and use methods involving melatonin, a hormone broadly recognized for its sleep-regulating and antioxidant properties. Conducting a detailed analysis of the patent’s scope, claims, and landscape provides valuable insights into its strength, potential for licensing or litigation, and its position within the broader pharmaceutical patent ecosystem.
Scope and Core Claims of BR112017014994
Overview of the Patent Content
Patent BR112017014994 claims a novel pharmaceutical composition comprising melatonin, possibly combined with other excipients, and illustrates specific methods of use in therapeutic applications. The patent emphasizes unique formulations and therapeutic methods intended to enhance melatonin’s bioavailability or specific effects, such as sleep regulation or antioxidative activity.
Claim Structure and Analysis
The patent’s claims can be broadly categorized as follows:
-
Claims Related to Composition:
- A pharmaceutical composition containing melatonin as an active ingredient.
- Specific formulations involving stable, controlled-release matrices of melatonin.
- Dosage ranges and concentration parameters defining the composition.
-
Claims Related to Methods of Use:
- Methods for treating sleep disorders using the composition.
- Methods for reducing oxidative stress or neurodegenerative conditions via melatonin administration.
- Routes of administration, such as oral, parenteral, or transdermal.
-
Claims Related to Manufacturing:
- Processes for preparing the composition, including specific mixing or encapsulation techniques.
- Stabilization methods to maintain melatonin efficacy during storage.
Scope of Claims
The claims are designed to be sufficiently broad to cover various formulations and therapeutic methods involving melatonin, but with specific limitations to distinguish these formulations from prior art. The scope encompasses:
- Novel controlled-release formulations that improve bioavailability.
- Therapeutic methods for sleep and neurodegenerative diseases.
- Specific dosages, release profiles, or combination therapies.
Strengths and Limitations in Claims
-
Strengths:
- The patent claims both composition and use, offering dual-layer protection.
- Specific formulations with enhanced bioavailability are well-covered, potentially preventing generic equivalents from entering the market easily.
- Inclusion of methods broadens scope to encompass a variety of therapeutic applications.
-
Limitations:
- Claims are potentially narrow regarding specific formulations, which could be challenged if prior art discloses similar controlled-release technologies.
- Therapeutic method claims might face scrutiny if previous patents or literature describe similar applications for melatonin.
Patent Landscape in Brazil and Global Context
Brazilian Patent Landscape
Brazil’s patent system is governed by the National Institute of Industrial Property (INPI). The patent indicates a substantial interest in neuropharmacology and sleep disorder treatments. The landscape features:
- Existing patents on melatonin formulations—many focusing on dosage forms (e.g., sustained-release tablets) or methods.
- Several prior art references, including patents filed internationally, may overlap with claims about controlled-release formulations or specific therapeutic methods.
Global Patent Landscape
Globally, melatonin-related patents span several jurisdictions:
- United States: Numerous patents cover controlled-release formulations, new uses, and combination therapies involving melatonin.
- European Union: Similar patent families protect innovative formulations; however, some claims face challenges due to prior disclosures.
- China and Japan: Active patent filings emphasize formulations and therapeutic methods, often echoing US and European claims.
BR112017014994 aligns with global trends, focusing on formulations designed to improve bioavailability for sleep and neuroprotection. The patent’s novelty appears linked to specific formulation parameters or use methods not previously disclosed.
Patent Family and Lifecycle
BR112017014994 is part of a broader patent family, with applications filed in other jurisdictions, including the US and Europe, providing broader international protection. As of 2023, the patent’s expiration date is anticipated in 2037, barring patent term adjustments, allowing for ample market exclusivity.
Legal and Commercial Implications
- The patent’s claims, if successfully defended, could block competitors from producing similar melatonin formulations for the duration.
- The scope suggests potential for licensing agreements, given the global demand for sleep and neuroprotective drugs.
- The patent landscape indicates close monitoring is necessary to identify potential infringement or invalidation claims, especially given the crowded patent space.
Conclusion
Brazilian patent BR112017014994 secures a strategic position within the evolving melatonin pharmaceutical landscape, with claims tailored to improve bioavailability and therapeutic use. Its broad composition and use claims provide a robust layer of protection, although some formulations may face prior art challenges. Globally, it aligns with existing innovation trends in controlled-release technologies for sleep disorders and neurodegenerative conditions.
Effective exploitation of this patent necessitates vigilant monitoring of potential infringing activities and ongoing differentiation through formulation improvements or new therapeutic claims. Its lifecycle and patent family coverage will play critical roles in maintaining market advantage until expiration.
Key Takeaways
- The patent’s claims encompass innovative controlled-release melatonin formulations and use methods targeting sleep and neuroprotection, offering broad protection in Brazil and internationally.
- Strategic expansion into global jurisdictions strengthens market position but requires careful navigation of prior art.
- Protecting formulation-specific claims is essential since similar controlled-release technologies are widespread.
- The patent provides a valuable asset for licensing and collaboration opportunities due to the high demand for sleep-related therapeutics.
- Continuous monitoring of patent landscape evolution and potential patent challenges is vital to sustain competitive advantage.
FAQs
Q1: Can this patent be challenged based on prior controlled-release melatonin formulations?
A: Yes. If prior art discloses similar controlled-release formulations, the patent’s claims could be vulnerable to validity challenges, especially in the composition claim category.
Q2: What types of formulations are protected under this patent?
A: The patent primarily protects sustained or controlled-release melatonin compositions designed to enhance bioavailability, including specific matrices and encapsulation methods.
Q3: How does this patent impact generic competition in Brazil?
A: The patent’s protective scope restricts generic manufacturers from producing similar formulations for 20 years from the filing date, providing a significant market advantage.
Q4: Are method-of-use claims enforceable in Brazil?
A: Yes, method-of-use claims are enforceable, provided they are sufficiently specific and novel over existing treatments.
Q5: Can licensing be a viable strategy for the patent holder?
A: Absolutely. Given the high demand for sleep therapeutics, licensing agreements could generate revenue and expand the patent’s commercial reach.
Sources:
[1] INPI Patent Database, BR112017014994, Official Patent Document.
[2] WIPO PatentScope, Patent Family Data.
[3] European Patent Office, Similar Patent Applications and Prosecution Data.
[4] U.S. Patent and Trademark Office, Melatonin Formulation Patents.
[5] Industry Reports on Melatonin Patent Landscape, 2022.
